Drug exposure | 1st trimester exposure (%) | Any antepartum exposure (%) |
---|---|---|
ART = antiretroviral therapy, NRTI = nucleoside analogue reverse transcriptase inhibitor, NNRTI = non-nucleoside analogue reverse transcriptase inhibitor, PI = protease inhibitor. | ||
*Percentages in italics refer to exposure subgroup. | ||
†Includes folate antagonists (32), aciclovir (2), benzodiazepine (4), methadone (4), amitryptiline, chloroquine, prednisolone, dapsone (2), rifamycins (4), isoniazid (2), pyrazinamide, ethambutol, erythromycin, ferrous sulphate (2), thyroxine, cephalosporin, clarithromycin, metronidazole, nitrofurantoin, roaccutane, ranitidine, atenolol, enalapril. | ||
‡Includes co-trimoxasole (29), pyrimethamine (2), carbamezepine (1). | ||
ART | 28 (14.4%) | 167 (85.6%) |
Zidovudine monotherapy* | 2 (7.1%) | 89 (45.6%) |
Dual NRTI | 12 (42.9%) | 25 (12.8%) |
Dual NRTI + NNRTI | 3 (10.7%) | 26 (13.3%) |
Dual NRTI + PI | 9 (32.2%) | 22 (11.3%) |
All three ART classes | 2 (7.1%) | 5 (2.6%) |
Other medication | 44 (22.6%)† | 84 (43.1%) |
Folate antagonists‡ | 32 (16.4%) | 57 (29.2%) |
ART and folate antagonists | 13 (6.7%) | 51 (26.2%) |